^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    decitabine/ tetrahydrouridine (EPI01)

    i
    Other names: EPI01, EPI 01, NN7533, NN 7533, Eclipse, NDec
    Company:
    EpiDestiny, Novo Nordisk
    Drug class:
    Cytidine deaminase inhibitor, DNA methylation inhibitor
    Related drugs:
    3d
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=44, Completed, Novo Nordisk A/S | Recruiting --> Completed
    Trial completion
    |
    decitabine/ tetrahydrouridine (EPI01)
    7ms
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=48, Recruiting, Novo Nordisk A/S | Not yet recruiting --> Recruiting
    Enrollment open
    |
    decitabine/ tetrahydrouridine (EPI01)
    10ms
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Novo Nordisk A/S
    New P1 trial
    |
    decitabine/ tetrahydrouridine (EPI01)
    1year
    ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
    P2, N=84, Recruiting, Novo Nordisk A/S | Trial primary completion date: Nov 2023 --> Oct 2024
    Trial primary completion date
    |
    hydroxyurea • decitabine/ tetrahydrouridine (EPI01)